|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||0.25|
|Earnings date||13 Feb 2023 - 17 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.